METTL3 and hepatocellular carcinoma: Of note, METTL3 is frequently reported to play an oncogenic role in HCC [43]; however, in agreement with a recent study showing that METTL3 depletion contributes to the sorafenib resistance in HCC [20], our data also identified METTL3 as a negative regulator of sorafenib resistance.